Insider trading

Following insiders.

Send me real-time posts from this site at my email

Oppenheimer Feels Positive About VistaGen's 'Best-In-Class' Antidepressant, Sets $6 Target

Shares of VistaGen Therapeutics Inc VTGN 56.95% rocketed up over 40 percent to $1.36 in after-hours trading on Thursday — a mere fraction of the 500 percent upside implied by a late-day note from Oppenheimer.

Oppenheimer’s Jay Olson initiated coverage on VistaGen with an Outperform rating and $6 price target. Source

Some consolidation is possible. However, it's better to wait for more clear signals. We can probably expect a downside with gap-closing in the nearest time.